Benjamin Ebert, President and CEO at Dana-Farber Cancer Institute, shared on LinkedIn:
“Transforming cancer care takes exceptional people willing to bring their expertise together around a shared vision for what is possible.
The new breast cancer care model being launched through the collaboration between Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC) is a powerful example of what can happen when talented clinicians, researchers, and multidisciplinary teams work together to put patients first.
A special recognition to Elizabeth Mittendorf, Chief of Multi-Disciplinary Oncology at Dana-Farber and Chief of the Division of Breast Surgery at BIDMC, whose leadership across both institutions is helping bring this vision to life, and to the outstanding team of breast surgeons at BIDMC.
Also central to this effort is Sara Tolaney, Chief of Breast Oncology at Dana-Farber, whose leadership in advancing breast cancer research and clinical trials is helping expand access to innovative treatment options.
This collaboration brings together world leaders in the fields of medical oncology, breast surgery, radiation oncology, pathology, radiology, reconstructive surgery, and other specialties to deliver the highest level of personalized care.
This team is leading advances across the board, from basic science discoveries to new FDA approvals for breast cancer. The new collaboration has created an opportunity to rethink and optimize our care models, finding every opportunity to optimize the level of care and improve the patient experience.
We are all inspired by the exceptional people working together across disciplines and institutions, driven by a shared commitment to transforming the outcomes for patients.”
You can read FDA approvals for breast cancer care on OncoDaily:
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
